NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study

Phase 3

Terminated

Conditions: Heart Diseases
Arrhythmia
Atrial Fibrillation

Interventions: Device: Radiofrequency Ablation

Registration Number: NCT00721149

Lead Sponsor: Biosense Webster, Inc.

Brief Summary: This trial evaluates the safety and effectiveness of catheter ablation for PAF. The investigational catheter being studied is the NAVISTAR® THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL® Catheter was FDA-approved for commercial distribution in the U.S. for treating patients with Type I atrial flutter and drug refractory monomorphic sustained ventricular tachycardia post myocardial infarction. The catheter was approved for use in Europe for endocardial ablation for treating cardiac arrhythmias.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 10

Inclusion Criteria

Patients with symptomatic PAF who have had three (3) AF episodes in the six (6) months prior to enrollment, one of which must be documented. Documentation may include electrocardiogram (ECG), transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip.
Failure of at least one AAD for PAF [class I or III or AV nodal blocking agents such as beta blockers (BB) and calcium channel blockers (CCB)] as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AAD.
Signed Patient Informed Consent Form.
Age 18 years or older.
Able and willing to comply with all pre-, post- and follow-up testing and requirements.

Exclusion Criteria

Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non- cardiac cause.
Previous ablation for atrial fibrillation.
Patients on amiodarone therapy at any time during the previous six (6) months.
AF episodes that last longer than 30 days and are terminated via cardioversion.
Any valvular cardiac surgical procedure.
CABG procedure within the last 180 days (six months).
Awaiting cardiac transplantation or other cardiac surgery within the next 360 days (12 months).
Documented left atrial thrombus on imaging (e.g. TEE).
History of a documented thromboembolic event within the past one (1) year.
Diagnosed atrial myxoma.
Presence of implanted ICD.
Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable).
Acute illness or active systemic infection or sepsis.
Unstable angina.
Myocardial infarction within the previous 60 days (two months).
LVEF < 40%.
History of blood clotting or bleeding abnormalities.
Contraindication to anticoagulation (i.e. heparin or warfarin).
Contraindication to CT/MRA procedure.
Life expectancy less than 360 days (12 months).
Enrollment in an investigational study evaluating another device or drug.
Uncontrolled heart failure or NYHA class III or IV heart failure.
Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.
Presence of a condition that precludes vascular access.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
NaviStar ThermoCool	Radiofrequency Ablation	-

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects Who Exhibited no Documented Symptomatic Paroxysmal Atrial Fibrillation (PAF) Episodes From Study Day 91 Through Day 361.	From study day 91 through day 361	A subject who exhibited no documented symptomatic PAF episodes was one who 1) had 2 or fewer repeat ablations within 90 days of the initial ablation with investigational catheter; 2) had an addition of antiarrhythmic medication which was previously ineffective for atrial fibrillation and did not exceed the previous historical maximum dosage (24 hour total dose); 3) was on atrioventricular nodal blocking agents such as beta blockers and/or calcium channel blockers and might be maintained at the current dose (ie, did not exceed previous historical maximum dosage (24 hour total dose).
The Percentage of Subjects Who Experienced Incidences of Early Onset (Within 7 Days of Ablation Procedure) Catheter-related Adverse Events.	within 7 days of ablation procedure	Catheter-related adverse events include death, myocardial infarction, pulmonary vein stenosis, diaphragmatic paralysis, atrio-esophageal fistula, transient ischemic attack, stroke, cerebrovascular accident, thromboembolism, pericarditis, cardiac tamponade, pericardial effusion, pneumothorax, atrial perforation, vascular access complications, pulmonary edema, hospitalization (initial and prolonged), and heart block.

Secondary Outcome Measures

Name	Time	Method
Percentage of Subjects Who Achieved Acute Success	Day 91 - 361	Acute success is defined as the confirmation of entrance block in all targeted pulmonary veins. Acute failure is defined as subjects who have a non-investigational catheter used for ablation of any atrial fibrillation targets or subjects who undergo more than 2 repeat ablation procedures or an ablation procedure beyond day 90.
24-hour Holter Data	1 year
TTM Data	1 year
Percentage of Subjects Who Responded to Quality of Life Assessment	1 year	SF 36 Symptom Frequency and Severity Checklist

Trial Locations

Locations (4): Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
University of Rochester Medical Center
🇺🇸
Rochester, New York, United States
Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
Ohio State University Medical Center
🇺🇸
Columbus, Ohio, United States